



Supplementary Figure S3. CDC42 enzymatic activity inhibition led to decidualization impairment without inducing cellular senescence. (A–C) Representative bright field images of primary endometrial stromal cells (EnSCs) treated with DMSO or 10 μ M ML141 following with 72 h of 8Br-cAMP+MPA treatment. Quantitative analysis of cell major axis and the ratio of cell major axis to minor axis. **(D)** Representative images of F-actin immunofluorescence staining in primary EnSCs treated with DMSO or 10 μ M ML141 following with 72 h of 8Br-cAMP+MPA treatment, with continuous addition of inhibitors during decidualization. **(E and F)** Level of PRL and IGFBP1 secretion in primary EnSCs treated with DMSO or 10 μ M ML141 following with 72 h of 8Br-cAMP+MPA treatment, with continuous addition of inhibitors during decidualization. **(G and H)** SA- β -gal staining of primary EnSCs treated with DMSO or 10 μ M ML141 following with 96 h of 8Br-cAMP+MPA treatment, with continuous addition of inhibitors during decidualization. Fold change of integrated optical density for SA- β -gal staining. **(I–K)** Expression of CDC42, CDKN2A, and CDKN1A mRNA levels in primary EnSCs treated with DMSO or 10 μ M ML141 following with 96 h of 8Br-cAMP+MPA treatment, with continuous addition of inhibitors during decidualization. Decidualization induction medium supplemented with DMSO or ML141 was replaced every day. **(L–O)** Level of IL6, IL8, CLU, and sST2 secretion in primary EnSCs treated with DMSO or 10 μ M ML141 following with 72 h of 8Br-cAMP+MPA treatment, with continuous addition of inhibitors during decidualization. Mean \pm SEM. * P <0.05, ** P <0.01, *** P <0.001. ns, not significant. ANOVA with Tukey’s multiple comparisons test.